<DOC>
	<DOCNO>NCT01064687</DOCNO>
	<brief_summary>The purpose study determine LY2189265 effective safe reduce hemoglobin A1c ( HbA1c ) , compare placebo ( medicine ) , exenatide participant Type 2 Diabetes . The participant must also take metformin pioglitazone .</brief_summary>
	<brief_title>A Study Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>During study , participant develop persistent , severe hyperglycemia despite full compliance assign therapeutic regimen , participant receive additional therapeutic intervention initiation alternative antihyperglycemic medication follow study drug discontinuation ( rescue therapy ) . Participants receive rescue therapy include analysis population , measurement obtain prior begin rescue therapy include specified analysis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes ( T2D ) well control 1 , 2 , 3 oral antidiabetic medication 1 . Glycosylated hemoglobin ( HbA1c ) great equal 7 less equal 11 take 1 oral antidiabetic medication 2 . HbA1c great equal 7 less equal 10 2 3 oral antidiabetic medication Able tolerate minimum dose 1500 milligram ( mg ) metformin day 30 mg pioglitazone per day . Willing inject subcutaneous ( SC ) medication 2 time per day Stable weight 3 month prior screen Body mass index ( BMI ) 23 45 kilogram per meter square ( kg/m^2 ) Females child bear potential must test negative pregnancy screen serum pregnancy test willing use reliable method birth control study 1 month follow last dose study drug . Type 1 Diabetes HbA1c equal less 6.5 randomization randomization Chronic insulin use Taking drug promote weight loss prescription counter Taking systemic steroid great 14 day except topical , eye , nasal , inhaled History fluid retention edema History Heart Failure New York Heart Classification II , III , IV acute myocardial infarction stroke within 2 month screen Gastrointestinal ( GI ; stomach ) problem diabetic gastroparesis bariatric surgery ( stomach staple ) chronically take drug directly affect GI motility Hepatitis liver disease alanine transaminase ( ALT ) great 2.5 time upper limit normal Acute chronic pancreatitis form Renal disease ( kidney ) serum creatinine great equal 1.5 milligram per deciliter ( mg/dL ) males great equal 1.4 mg/dL female , creatine clearance le 60 milliliter per minute ( mL/min ) History ( include family ) type 2A 2B Multiple Endocrine Neoplasia ( MEN 2A 2B ) medullary ccell hyperplasia thyroid cancer A serum calcitonin great equal 20 picograms per milliliter ( pg/mL ) screen Significant active autoimmune disease Lupus Rheumatoid Arthritis History active malignancy except skin situ cervical prostate cancer within last 5 year Sickle cell , hemolytic anemia , hematological condition may interfere HbA1c test Organ transplant except cornea Have enrol another clinical trial within last 30 day Have previously sign informed consent participate LY2189265 ( dulaglutide ) study Have take glucagonlike peptide 1 ( GLP1 ) receptor agonist within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>